Novozymes Biopharma, part of Novozymes A/S, a world
leader in bioinnovation, has announced that it has expanded its partnership
with Nottingham-based research and development company, Upperton Limited, to
offer customers a new albumin conjugation solution. By linking drugs to
Novozymes' new Recombumin Flex recombinant human albumin (rAlbumin), using
conjugation, their pharmacokinetic and pharmacodynamic properties can be
dramatically enhanced. As a result, manufacturers can benefit from the ability
to tailor and control the half-life of drugs to fit patients' medical needs.
"Novozymes is delighted to unveil Recombumin Flex
along with our new conjugation solution in partnership with Upperton
Limited," says Dave Mead, Business Development Director at Novozymes
Biopharma. "Novozymes has enjoyed a successful relationship with Upperton
over the past 10 years and its expertise and experience in the conjugation of
proteins, combined with our experience of protein engineering and production,
will help customers to design drugs with tailored serum half-life and fewer
side-effects. This will result in improved dosing regimes for the patient and a
reduction in overall costs for the healthcare provider."
By manipulating the interaction of albumin with its
receptor, the neonatal Fc receptor (FcRn), Novozymes can produce modified
albumins that bind with greater or lesser affinities, meaning a flexible
half-life. Increasing the serum half-life of a drug may reduce the frequency of
injections a patient receives or even reduce the amount of drug delivered,
thereby significantly reducing toxic side-effects and increasing patient
acceptance.
Upperton has demonstrated that proteins, peptides and
small molecule APIs can be covalently attached to recombinant human albumin
using a range of chemistries. Additionally, once drugs have been linked to the
recombinant human albumin carrier, they exhibit dramatically improved
pharmacokinetic and pharmacodynamic properties. Combining Novozymes' unique IP
and know-how around the albumin molecules themselves with Upperton's
rP-conjugateT albumin conjugation chemistry knowledge, enables the companies to
work closely with customers to design and implement the best chemical linking
approach for their molecule. As a result, Novozymes can provide partners with a
unique service from initial product concept through to in vivo testing for
developing novel drugs.
Richard Johnson, founder and CEO of Upperton Limited,
comments "By combining Novozymes' and Upperton's unmatched expertise in
our respective fields, we have developed a solution that solves industry
challenges by enabling a tunable half-life that offers control and flexibility
and has the potential to improve overall treatment efficacy."
To learn more about Novozymes' Recombumin Flex
technology, please visit
www.biopharma.novozymes.com.
To find out more about Upperton Limited, please visit
www.upperton.com.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.